Citigroup’s Lexicon Pharmaceuticals LXRX Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q1 | $260K | Buy |
166,398
+74,728
| +82% | +$109K | ﹤0.01% | 3875 |
|
|
2025
Q4 | $105K | Buy |
91,670
+73,551
| +406% | +$101K | ﹤0.01% | 4302 |
|
|
2025
Q3 | $24.5K | Sell |
18,119
-30,425
| -63% | -$34.5K | ﹤0.01% | 4757 |
|
|
2025
Q2 | $45.9K | Sell |
48,544
-48,424
| -50% | -$31.4K | ﹤0.01% | 4806 |
|
|
2025
Q1 | $44.7K | Sell |
96,968
-9,818
| -9% | -$6.19K | ﹤0.01% | 4904 |
|
|
2024
Q4 | $78.9K | Buy |
106,786
+17,041
| +19% | +$20.5K | ﹤0.01% | 4938 |
|
|
2024
Q3 | $141K | Buy |
89,745
+56,615
| +171% | +$101K | ﹤0.01% | 4588 |
|
|
2024
Q2 | $55.7K | Buy |
33,130
+15,582
| +89% | +$28K | ﹤0.01% | 4517 |
|
|
2024
Q1 | $42.1K | Sell |
17,548
-207,450
| -92% | -$446K | ﹤0.01% | 4705 |
|
|
2023
Q4 | $344K | Buy |
224,998
+188,983
| +525% | +$225K | ﹤0.01% | 3646 |
|
|
2023
Q3 | $39.3K | Buy |
36,015
+2,528
| +8% | +$4.44K | ﹤0.01% | 4213 |
|
|
2023
Q2 | $76.7K | Buy |
33,487
+29,442
| +728% | +$78.2K | ﹤0.01% | 4369 |
|
|
2023
Q1 | $9.83K | Sell |
4,045
-172
| -4% | -$394 | ﹤0.01% | 4742 |
|
|
2022
Q4 | $8.05K | Sell |
4,217
-420
| -9% | -$894 | ﹤0.01% | 4912 |
|
|
2022
Q3 | $11K | Sell |
4,637
-11,916
| -72% | -$33K | ﹤0.01% | 4956 |
|
|
2022
Q2 | $31K | Buy |
16,553
+7,877
| +91% | +$15K | ﹤0.01% | 4780 |
|
|
2022
Q1 | $18K | Sell |
8,676
-14,931
| -63% | -$41.4K | ﹤0.01% | 5212 |
|
|
2021
Q4 | $93K | Buy |
23,607
+14,672
| +164% | +$71.3K | ﹤0.01% | 4769 |
|
|
2021
Q3 | $43K | Sell |
8,935
-2,660
| -23% | -$10.9K | ﹤0.01% | 4817 |
|
|
2021
Q2 | $53K | Buy |
11,595
+8,124
| +234% | +$39.1K | ﹤0.01% | 4791 |
|
|
2021
Q1 | $20K | Sell |
3,471
-88,416
| -96% | -$612K | ﹤0.01% | 5255 |
|
|
2020
Q4 | $314K | Sell |
91,887
-12,296
| -12% | -$23.5K | ﹤0.01% | 4618 |
|
|
2020
Q3 | $150K | Buy |
104,183
+91,950
| +752% | +$164K | ﹤0.01% | 4823 |
|
|
2020
Q2 | $24K | Sell |
12,233
-6,370
| -34% | -$12.5K | ﹤0.01% | 6481 |
|
|
2020
Q1 | $36K | Buy |
18,603
+715
| +4% | +$2.13K | ﹤0.01% | 6271 |
|
|
2019
Q4 | $74K | Sell |
17,888
-30,505
| -63% | -$117K | ﹤0.01% | 6009 |
|
|
2019
Q3 | $146K | Sell |
48,393
-93,931
| -66% | -$291K | ﹤0.01% | 5402 |
|
|
2019
Q2 | $895K | Buy |
142,324
+29,885
| +27% | +$179K | ﹤0.01% | 3763 |
|
|
2019
Q1 | $626K | Sell |
112,439
-285,205
| -72% | -$1.73M | ﹤0.01% | 3940 |
|
|
2018
Q4 | $2.64M | Buy |
397,644
+129,687
| +48% | +$1.05M | ﹤0.01% | 2406 |
|
|
2018
Q3 | $2.86M | Buy |
267,957
+99,771
| +59% | +$1.14M | ﹤0.01% | 2397 |
|
|
2018
Q2 | $2.02M | Buy |
168,186
+108,333
| +181% | +$1.11M | ﹤0.01% | 2668 |
|
|
2018
Q1 | $513K | Sell |
59,853
-18,105
| -23% | -$167K | ﹤0.01% | 3966 |
|
|
2017
Q4 | $770K | Buy |
77,958
+4,866
| +7% | +$50.6K | ﹤0.01% | 3614 |
|
|
2017
Q3 | $899K | Buy |
73,092
+29,162
| +66% | +$431K | ﹤0.01% | 3490 |
|
|
2017
Q2 | $723K | Buy |
43,930
+1,819
| +4% | +$28.2K | ﹤0.01% | 3637 |
|
|
2017
Q1 | $604K | Sell |
42,111
-108,989
| -72% | -$1.62M | ﹤0.01% | 3707 |
|
|
2016
Q4 | $2.09M | Buy |
151,100
+124,391
| +466% | +$2M | ﹤0.01% | 2893 |
|
|
2016
Q3 | $483K | Buy |
26,709
+13,044
| +95% | +$210K | ﹤0.01% | 3920 |
|
|
2016
Q2 | $196K | Sell |
13,665
-28,861
| -68% | -$391K | ﹤0.01% | 4520 |
|
|
2016
Q1 | $508K | Buy |
42,526
+36,492
| +605% | +$383K | ﹤0.01% | 4100 |
|
|
2015
Q4 | $80K | Sell |
6,034
-45,219
| -88% | -$556K | ﹤0.01% | 5550 |
|
|
2015
Q3 | $550K | Buy |
51,253
+36,460
| +246% | +$398K | ﹤0.01% | 3656 |
|
|
2015
Q2 | $119K | Sell |
14,793
-1,304
| -8% | -$9.58K | ﹤0.01% | 4864 |
|
|
2015
Q1 | $106K | Sell |
16,097
-5,787
| -26% | -$39.5K | ﹤0.01% | 4989 |
|
|
2014
Q4 | $139K | Buy |
21,884
+17,876
| +446% | +$144K | ﹤0.01% | 4972 |
|
|
2014
Q3 | $40K | Sell |
4,008
-283
| -7% | -$3.02K | ﹤0.01% | 5451 |
|
|
2014
Q2 | $48K | Sell |
4,291
-12,056
| -74% | -$129K | ﹤0.01% | 5196 |
|
|
2014
Q1 | $198K | Buy |
16,347
+361
| +2% | +$4.61K | ﹤0.01% | 4332 |
|
|
2013
Q4 | $202K | Buy |
15,986
+1,331
| +9% | +$21.2K | ﹤0.01% | 4647 |
|
|
2013
Q3 | $244K | Buy |
14,655
+12,050
| +463% | +$202K | ﹤0.01% | 3994 |
|
|
2013
Q2 | $40K | Buy |
+2,605
| New | +$39.6K | ﹤0.01% | 5499 |
|
Other funds holding LXRX
AG
SL
SC
VCM
Citigroup's LXRX Position: Q1 2026 in Review
Citigroup increased its Lexicon Pharmaceuticals (LXRX) stake by 82% in Q1 2026, buying an estimated $109K and bringing the position to 166,398 shares worth $260K. The position accounts for ﹤0.01% of the portfolio, ranked #3875.
Citigroup first reported a position in LXRX in Q2 2013 and has held it in 52 quarters since. The position peaked at $2.86M in Q3 2018. 136 funds tracked by Wall St. Rank hold LXRX as of Q1 2026.
- Citigroup held 166,398 shares of Lexicon Pharmaceuticals worth $260K as of Q1 2026.
- Citigroup bought 74,728 Lexicon Pharmaceuticals shares in Q1 2026, an estimated $109K.
- Lexicon Pharmaceuticals made up ﹤0.01% of Citigroup's portfolio in Q1 2026, its #3875 holding.
- Citigroup first reported a position in Lexicon Pharmaceuticals in Q2 2013 and has held it in 52 quarters since.
- Citigroup's Lexicon Pharmaceuticals position peaked at $2.86M in Q3 2018.
- 136 funds tracked by Wall St. Rank held Lexicon Pharmaceuticals as of Q1 2026.
Based on Citigroup's 13F filing for Q1 2026, filed 11 May 2026.